REPL Replimune Group Inc.

+0.25  (+2%)
Previous Close 13
Open 12.98
Price To Book 3.22
Market Cap 419,576,912
Shares 31,666,182
Volume 10,018
Short Ratio
Av. Daily Volume 27,712

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data to be presented 4Q 2019.
RP1 and nivolumab
Solid tumors
Phase 2 trial to be initiated in August.
RP1 and cemiplimab
Cutaneous squamous cell carcinoma (CSCC)
Phase 1 trial to be initiated 3Q 2019.
RP2 and nivolumab
Solid tumors